Topic: clinical manuacturing
PCI Pharma Services debuts expansion of its plant in Rockford, Illinois.
Friday, September 6, 2019
This industry survey seeks to gain insight on trial sponsors’ perspective on offering a DTP option and their current level of awareness and understanding of any factors that may influence their ability to do so.
Tuesday, July 16, 2019
In part two of this webinar series on the 505(b)(2) pathway, Ken delves deeper into IND-enabling activities including CMC, toxicology and PK/PD.
With drug development in China growing rapidly, Catalent has doubled down on its clinical supply capabilities in Shanghai.
Thursday, May 16, 2019
If your company is looking to adopt a new eCOA solution or have issues with your current one, this webinar is a must attend.
A Florida CDMO will build a 40,000-square-foot biomanufacturing facility so that it can handle commercial production for its biopharma clients.
Abzena will invest $20 million in a cell manufacturing facility, and Catalent is spending $2.5 million on a clinical supply facility in China.
Cambrex is expanding its facilities in North Carolina, which will employ 150 people when complete.
CDMO Catalent will pay about $133 million for Boston-based Juniper Pharmaceuticals.
Particle Sciences will have commercial manufacturing capabilities operating at its Pennsylvania facility by the end of the year and will add 30 jobs.